Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04651452 · ClinicalTrials.gov registry record · NA
Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors
A NA study of Breast Cancer, sponsored by Carnegie Mellon University.
- Active
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 1
- Study location
NCT04651452: Active NA study of Breast Cancer, sponsored by Carnegie Mellon University.
NCT04651452 is a NA study of Breast Cancer that is active but no longer recruiting, run by Carnegie Mellon University. The registered enrollment target is 250 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04651452, a NA study of Breast Cancer, is active but no longer recruiting, sponsored by Carnegie Mellon University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
Aromatase inhibitors are a powerful medication for reducing the risk of recurrence and increasing survival in postmenopausal breast cancer patients. However, these medications can lead to intolerable side effects, poor medication adherence, and increased stress levels. This project's broad objective is to assess whether an intervention can improve medication adherence and reduce physical symptoms and stress in breast cancer patients prescribed aromatase inhibitors. Participants will be randomly assigned to a values affirmation or reflective journaling condition. Interventions will be writing-based, one essay per month for six months. Physical symptoms and perceived stress will be assessed at baseline, post-intervention (one month after the intervention), and follow-up (six months from the post-intervention assessment and seven months after the end of the intervention). Furthermore, an electronic pill bottle will continuously assess daily compliance so that medication adherence rates during the intervention, post-intervention, and follow-up can be calculated.
Conditions Studied
Interventions
- BEHAVIORAL Value Affirmation
- BEHAVIORAL Reflective Journaling
Study Locations (1)
Pennsylvania
- Carnegie Mellon University - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04651452
The ClinicalTrials.gov registry entry for NCT04651452 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Carnegie Mellon University, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Value Affirmation is the first listed.
NCT04651452 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04651452 about?
NCT04651452 is a clinical study titled "Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors". Aromatase inhibitors are a powerful medication for reducing the risk of recurrence and increasing survival in postmenopausal breast cancer patients. However, these medications can lead to intolerable side effects, poor medication adherence, and increased stress levels. This project's broad objective...
What is the current status of trial NCT04651452?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2021-02-01. Estimated completion is 2026-04-30.
What conditions does trial NCT04651452 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT04651452?
The interventions under investigation include: Value Affirmation (BEHAVIORAL), Reflective Journaling (BEHAVIORAL).
Who is sponsoring clinical trial NCT04651452?
This trial is sponsored by Carnegie Mellon University, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04651452 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.